Graceptor is a once-daily modified release formulation of Astellas’s Prograf (tacrolimus, twice-daily formulation). Tacrolimus works as an immunosuppressant by inhibiting activation of T-cell.
Graceptor maintains its efficacy and safety at the similar level with the existing drug, Prograf, said Astellas. Once-daily administration possibly contributes to reduce physical and mental stress for patients who need to take several different medications in a long term. It is expected to improve compliance with its more convenient once-daily dosing option, and may lead to improve long-term outcomes of transplantation.
Once-daily formulation of Prograf has been available with the brand name Advagraf in 19 countries worldwide including Europe. Astellas expects to provide a new option for transplant medication with the new lineup for Prograf family.